United States Court of Appeals for the Federal Circuit

______________________

February 9. 2012

ERRATA

______________________ 2011-1182, -1183, -1184, -1185, -1186, -1187, -1188, -1189,

-1190

ASTRAZENECA PHARMACEUTICALS LP, ASTRAZENECA AB, IPR PHARMACEUTICALS INC., and THE BRIGHAM AND WOMEN’S HOSPITAL, INC.,

Plaintiffs-Appellants,

v.

APOTEX CORP.,

Defendant-Appellee,

and

AUROBINDO PHARMA LIMITED,

Defendant-Appellee,

and

COBALT PHARMACEUTICALS INC.

and COBALT LABORATORIES INC.,

Defendants-Appellees,

and

GLENMARK GENERICS INC. USA,

Defendant-Appellee,

and

MYLAN PHARMACEUTICALS INC.,

Defendant-Appellee,

and

PAR PHARMACEUTICALS, INC.,

Defendant-Appellee,

and SUN PHARMACEUTICAL INDUSTRIES, LTD.,

Defendant-Appellee,

and

TEVA PHARMACEUTICALS USA, INC.,

Defendant-Appellee,

and

TORRENT PHARMA INC. and

TORRENT PHARMACEUTICALS LTD.,

Defendants.

______________________

Decided: February 24, 2012

Precedential Opinion

______________________ Please make the following change: Page 3, correction of Shane A. Brunner, Mechant & Gould, P.C. of Madison, Wisconsin, argued for defendant-appellee “Aurobindo Pharma Limited” H. Ketto Sabharwal to “H. Keeto Sabharwal”